by Client Pharma
May 18, 2017 3:26 pm
|
At the New York Academy of Sciences’ symposium on Equivalence of Complex Drug Products: Scientific and Regulatory Challenges, regulatory officials described how agencies approach evaluating complex generics for marketing approval. In 2015, almost 90% of prescriptions in the United States were for generics, according to the Generic Pharmaceutical Association. However, there are certain complex drug
by Client Pharma
April 18, 2017 1:00 pm
|
False medicines can present a huge health risk to the public. As well as potentially damaging the reputations of pharmaceutical companies, they can disrupt comparator sourcing and clinical trials services. The number of illegitimate and counterfeit medicines across the globe is becoming increasingly concerning, as they have even been appearing in the legitimate medical supply
by Client Pharma
April 3, 2017 1:10 am
|
Clinical trial supply is, to state the obvious, an expensive and multifaceted activity which continues to get more complex. Over the past 5 years, factors have extended this trend; for example: Changes in and development of legislation – New EU Clinical Trial regulations (No 536/2014), the Falsified Medicines Directive, US FDA Drug Supply Chain Security
by Client Pharma
February 7, 2017 10:06 am
|
It has been noted that older, off-patent drugs are becoming increasingly expensive. But what are the underlying causes of the problem and how can policymakers address it? In August 2015, a pharmaceutical company increased the price of Daraprim (pyrimethamine), its newly acquired 62-year-old infectious disease drug. Due to the limited patient population and lack of
by Client Pharma
January 23, 2017 11:28 am
|
We are very pleased to announce the appointment of Mark Johnson as the new Director of Clinical Trial Services at Client Pharma CTS. Mark’s considerable knowledge of the global pharmaceutical supply chain and experience within the industry furthers Client Pharma CTS’s ability to support manufacturers, sponsors, biotechs, CROs and patients alike. He will be playing
by Client Pharma
January 17, 2017 1:58 pm
|
Researchers from the University of Massachusetts and Newcastle University have argued that clinical trial design for biosimilars needs to be standardized after highlighting differences in the safety evaluations and findings between clinical trials for these drugs. The researchers identified that different designs have been employed in some phase III clinical trials when comparing biosimilar TNF
by Client Pharma
January 6, 2017 12:35 pm
|
The cost of drugs to treat cancer has been increasing significantly around the world. This is partly due to the introduction of new therapies to treat the condition; however, with so much research, development and innovation being made there is uncertainty around how health care systems will be able to afford these advancements. Following the
by Client Pharma
October 10, 2016 4:03 pm
|
In recent years, drug prices have come under increased global scrutiny. As globally people live longer and cures for previously incurable conditions are found, the need for affordable and timely access to medicine has never been more essential. Although the price of medicine is not strictly within the remit of regulatory bodies, drug regulators can
by Client Pharma
September 29, 2016 1:38 pm
|
Client-Pharma will be visiting CPHI Barcelona from 4-6th October. The exhibition, together with co-located events ICSE, InnoPack, P-MEC and FDF, will be a great opportunity for Client-Pharma to meet with existing and potential clients and stay up to date on all the latest industry trends and market news. CPHI Barcelona is the world’s leading pharmaceutical platform. Taking
by Client Pharma
July 21, 2016 12:15 pm
|
Japan has been named an emerging market for biosimilars as the uptake for some products is now on a par with generics. Over the past few years, biologics have gained significant traction in the pharmaceutical industry. By 2020 biosimilars are predicted to comprise 27% of the pharmaceutical market, generating a predicted revenue of $290 billion.
